JP2009521953A5 - - Google Patents

Download PDF

Info

Publication number
JP2009521953A5
JP2009521953A5 JP2008549562A JP2008549562A JP2009521953A5 JP 2009521953 A5 JP2009521953 A5 JP 2009521953A5 JP 2008549562 A JP2008549562 A JP 2008549562A JP 2008549562 A JP2008549562 A JP 2008549562A JP 2009521953 A5 JP2009521953 A5 JP 2009521953A5
Authority
JP
Japan
Prior art keywords
expression
patient
determining
smrp
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008549562A
Other languages
English (en)
Japanese (ja)
Other versions
JP5164855B2 (ja
JP2009521953A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/000215 external-priority patent/WO2007081767A2/en
Publication of JP2009521953A publication Critical patent/JP2009521953A/ja
Publication of JP2009521953A5 publication Critical patent/JP2009521953A5/ja
Application granted granted Critical
Publication of JP5164855B2 publication Critical patent/JP5164855B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008549562A 2006-01-04 2007-01-04 子宮内膜または子宮癌を評価するためのｈｅ４及びそのほかの生化学的マーカーの使用 Active JP5164855B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75613106P 2006-01-04 2006-01-04
US60/756,131 2006-01-04
PCT/US2007/000215 WO2007081767A2 (en) 2006-01-04 2007-01-04 Use of he4 and other biochemical markers for assessment of endometrial and uterine cancers

Publications (3)

Publication Number Publication Date
JP2009521953A JP2009521953A (ja) 2009-06-11
JP2009521953A5 true JP2009521953A5 (https=) 2010-02-25
JP5164855B2 JP5164855B2 (ja) 2013-03-21

Family

ID=38256906

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2008549562A Active JP5164855B2 (ja) 2006-01-04 2007-01-04 子宮内膜または子宮癌を評価するためのｈｅ４及びそのほかの生化学的マーカーの使用
JP2008549563A Active JP5221381B2 (ja) 2006-01-04 2007-01-04 卵巣癌を判定するためのｈｅ４及び他の生化学マーカーの使用
JP2012226640A Active JP5711196B2 (ja) 2006-01-04 2012-10-12 卵巣癌を判定するためのｈｅ４及び他の生化学マーカーの使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2008549563A Active JP5221381B2 (ja) 2006-01-04 2007-01-04 卵巣癌を判定するためのｈｅ４及び他の生化学マーカーの使用
JP2012226640A Active JP5711196B2 (ja) 2006-01-04 2012-10-12 卵巣癌を判定するためのｈｅ４及び他の生化学マーカーの使用

Country Status (7)

Country Link
US (8) US20070286865A1 (https=)
EP (6) EP1969136A4 (https=)
JP (3) JP5164855B2 (https=)
CN (3) CN106124765A (https=)
ES (2) ES2650244T3 (https=)
PL (1) PL2982761T3 (https=)
WO (2) WO2007081768A2 (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5731400A (en) * 1999-06-09 2000-12-28 Moltech Corporation Methods of preparing electrochemical cells
US7270960B2 (en) 2001-08-29 2007-09-18 Pacific Northwest Research Institute Diagnosis of ovarian carcinomas
EP1877795A4 (en) * 2005-05-02 2010-04-28 Brigham & Womens Hospital DIAGNOSTIC PROFILE MANUFACTURE OF SERUM ANTIBODIES
JP5164855B2 (ja) * 2006-01-04 2013-03-21 フジレビオ アメリカ、インク． 子宮内膜または子宮癌を評価するためのｈｅ４及びそのほかの生化学的マーカーの使用
MX2008009592A (es) * 2006-01-27 2008-09-08 Tripath Imaging Inc Metodos y composiciones para identificar pacientes con una probabilidad incrementada de tener cancer de ovario.
US8329399B2 (en) 2006-10-27 2012-12-11 Siu K W Michael Endometrial biomarkers
BRPI0808655A2 (en) * 2007-03-09 2018-10-23 Tripath Imaging, Inc. he4 monoclonal antibodies and methods for their use.
US8455189B2 (en) * 2007-03-29 2013-06-04 Jeffrey W. Allard Use of HE4 for assessment of breast cancers
CN101377502A (zh) * 2007-08-31 2009-03-04 北京科美东雅生物技术有限公司 肿瘤相关抗原72-4化学发光免疫分析测定试剂盒及其制备方法
WO2009099561A2 (en) * 2008-01-31 2009-08-13 The Brigham And Womens' Hospital, Inc. Urinary ca125 peptides as biomarkers of ovarian cancer
WO2009145815A2 (en) * 2008-04-01 2009-12-03 The Brigham And Women's Hospital, Inc. Biomarkers of ovarian cancer
JP6097688B2 (ja) * 2010-08-26 2017-03-15 ユニバーシティ オブ ワシントン スルー イッツ センター フォー コマーシャリゼーション 抗ｈｅ４抗体を検出するための方法、ならびにｈｅ４発現細胞と関連する状態の診断および／または予後判定のための方法
RU2650778C2 (ru) 2011-02-17 2018-04-17 Фуджиребио Диагностикс, Инк Композиции и способы применения для определения не4а
KR20140024860A (ko) * 2011-02-24 2014-03-03 버밀리언, 인코포레이티드 난소암에 대한 바이오마커 패널，진단 방법 및 시험 키트
CN102735840B (zh) * 2011-04-13 2014-06-04 中国医学科学院肿瘤研究所 用于诊断或筛查卵巢癌的试剂
WO2012170513A2 (en) * 2011-06-06 2012-12-13 Women & Infants' Hospital Of Rhode Island He4 based therapy for malignant disease
DE102012205164B4 (de) 2012-03-29 2021-09-09 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Projektionsdisplay und Verfahren zur Projektion virtueller Bilder
CN103575902B (zh) * 2012-08-03 2015-07-29 河南生生医疗器械有限公司 一种时间分辨荧光法四项综合检测卵巢癌试剂盒及其应用
CN102890083B (zh) * 2012-09-28 2016-08-10 辽宁科骏生物有限公司 化学发光底物溶液和含其的试剂盒及应用其的检测方法
CN104655858B (zh) * 2015-03-12 2016-02-10 德迈基生物技术（北京）有限公司 定量检测人附睾分泌蛋白-4的荧光免疫层析试剂盒及其制备方法
EP3273974A4 (en) 2015-03-26 2018-11-07 Women and Infants Hospital of Rhode Island Inc. Therapy for malignant disease
RU2585959C1 (ru) * 2015-06-22 2016-06-10 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ дифференциальной диагностики асцитно-инфильтративной формы рака яичников и абдоминального туберкулёза
US10267802B2 (en) 2015-09-23 2019-04-23 The Board Of Trustees Of The Leland Stanford Junior University Methods of prognosis and diagnosis of ovarian cancer
RU2624508C1 (ru) * 2016-06-29 2017-07-04 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ прогнозирования длительности ремиссии у больных раком вульвы
JP2019524706A (ja) * 2016-07-08 2019-09-05 ジェネンテック， インコーポレイテッド Ｍｕｃ１６陽性癌治療の応答性を評価するためのヒト精巣上体タンパク質４（ｈｅ４）の使用
CA3175499A1 (en) 2020-04-21 2021-10-28 University Of Rochester Inhibitors of human epididymus protein 4
CN111781364B (zh) * 2020-08-25 2023-07-21 北京信诺卫康科技有限公司 Wnt7a和HE4联合用作早期卵巢癌生物标志物以及试剂盒
CA3202255A1 (en) 2020-12-21 2022-06-30 Hayley WARSINSKE Markers for the early detection of colon cell proliferative disorders
US20240385195A1 (en) * 2022-04-08 2024-11-21 Ajou University Industry-Academic Cooperation Foundation Peptide for detecting ca125 and use thereof
US20240353411A1 (en) * 2022-04-08 2024-10-24 Ajou University Industry-Academic Cooperation Foundation He4 detecting peptide and use thereof
CN120254284B (zh) * 2025-06-03 2025-08-22 杭州广科安德生物科技有限公司 一种用于预测子宫内膜癌复发或转移风险的生物标志物及其应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
CA1289880C (en) * 1985-12-06 1991-10-01 Jeffrey L. Winkelhake Anti-human ovarian cancer immunotoxins and methods of use thereof
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5091513A (en) * 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) * 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
ATE243754T1 (de) 1987-05-21 2003-07-15 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5283173A (en) * 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
US6998106B1 (en) * 1998-12-01 2006-02-14 Duke University Radioconjugation of internalizing antibodies
US6770445B1 (en) 1999-02-26 2004-08-03 Pacific Northwest Research Institute Methods and compositions for diagnosing carcinomas
CA2369433A1 (en) 1999-02-26 2000-08-31 Pacific Northwest Research Institute Methods and compositions for diagnosing carcinomas
WO2002046765A2 (en) * 2000-11-08 2002-06-13 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer
US7270960B2 (en) * 2001-08-29 2007-09-18 Pacific Northwest Research Institute Diagnosis of ovarian carcinomas
US20030226155A1 (en) * 2001-08-30 2003-12-04 Biorexis Pharmaceutical Corporation Modified transferrin-antibody fusion proteins
KR101107765B1 (ko) * 2002-08-06 2012-01-25 싸이퍼젠 바이오시스템즈, 인코포레이티드 난소암의 검출을 위한 생물 마커의 용도
EP2315027A1 (en) * 2002-08-16 2011-04-27 Decision Biomarkers Incorporated Substrates for isolating, reacting and microscopically analyzing materials
WO2004072638A1 (en) * 2003-02-05 2004-08-26 Ciphergen Biosystems, Inc. Non-invasive assessment of intra-amniotic environment
WO2004101756A2 (en) * 2003-05-09 2004-11-25 Diadexus, Inc. Ovr110 antibody compositions and methods of use
CN1266475C (zh) * 2003-06-05 2006-07-26 马旭 一种用于诊断早期卵巢癌的四粘蛋白酶联免疫检测试剂盒
JP4912894B2 (ja) * 2004-02-19 2012-04-11 イェール ユニバーシティー プロテオーム技術を使用した癌タンパク質バイオマーカーの同定
WO2005098446A2 (en) * 2004-03-31 2005-10-20 The Johns Hopkins University Biomarkers for ovarian cancer
WO2006089125A2 (en) * 2005-02-16 2006-08-24 Dana-Farber Cancer Institute Methods of detecting ovarian cancer
CN101243319B (zh) * 2005-06-22 2016-01-06 约翰·霍普金斯大学 卵巢癌的生物标记：ctap3-相关蛋白质
WO2007002535A2 (en) * 2005-06-24 2007-01-04 Ciphergen Biosystems, Inc. Biomarkers for ovarian cancer
JP5164855B2 (ja) * 2006-01-04 2013-03-21 フジレビオ アメリカ、インク． 子宮内膜または子宮癌を評価するためのｈｅ４及びそのほかの生化学的マーカーの使用

Similar Documents

Publication Publication Date Title
JP2009521953A5 (https=)
Park et al. Diagnostic performances of HE4 and CA125 for the detection of ovarian cancer from patients with various gynecologic and non-gynecologic diseases
Li et al. Association of constitutive nuclear factor-jB activation with aggressive aspects and poor prognosis in cervical cancer
Kaura et al. Evaluation of the Pyruvate Kinase isoenzyme tumor (Tu M2‐PK) as a tumor marker for cervical carcinoma
Tendler et al. Increased carcinoembryonic antigen expression in cervical intraepithelial neoplasia grade 3 and in cervical squamous cell carcinoma
Deng et al. Analytical and clinical evaluation of CYFRA 21-1 by electrochemiluminescent immunoassay in head and neck squamous cell carcinoma
Zhang et al. Serum HE4 is more suitable as a biomarker than CA125 in Chinese women with benign gynecologic disorders
WO2022012293A1 (zh) 一种子宫内膜癌的外周血tcr标志物及其检测试剂盒和应用
CN103314299B (zh) 包含硫氧还蛋白1作为活性成分的用于诊断卵巢癌或肺炎的组合物及其应用
Park et al. The diagnostic utility of human papillomavirus-testing in combination with immunohistochemistry in advanced gynaecologic pelvic tumours: a new diagnostic approach
JP5548872B2 (ja) 大腸がん肝転移マーカー、及び試料中の大腸がん肝転移マーカーの分析方法
Terzi et al. New method: Are tumor markers in vaginal-washing fluid significant in the diagnosis of primary ovarian carcinoma
Mujtaba et al. Immunohistochemical evaluation of oestrogen receptors in adenoid cystic carcinoma of salivary gland
Lomnytska et al. Markers of breast and gynecological malignancies: The clinical approach of proteomics‐based studies
Szegedi et al. Endometrioid adenocarcinoma arising from adenomyosis: a case report.
Hussein Molecular detection of Epstein Barr Virus in Women with Breast cancer
Hassan et al. Determination of some biochemical markers for breast cancer women in Baghdad
Saeed et al. Thyroid Carcinoma Patients Correlated With Cytomegalovirus by using Insitu Hybridization
Sirsikar et al. Diagnostic and Prognostic Performance of Human Epididymis Secretary Protein-4 (HE4) in Cancer Treatment: A Review
Ajeel et al. Salivary CA125, Mucin-1, VEGF, and sFasL as Non-Invasive Biomarkers for Breast Cancer Detection and Prognosis: A Case-Control Study from Kirkuk, Iraq
Selvam et al. Molecular markers in cancer diagnosis and management: A Review
Speiser et al. Expression of cell cycle regulators and ki67 in patients with recurrence of early cervical cancer.
Park et al. Is human papilloma virus DNA and cytokeratin 19 useful as micrometastatic markers in cervical cancer patients only with intermediate risk factors?
Smrkolj et al. Endocervical adenocarcinoma in situ with ovarian metastasis
Devi et al. 00088: THE RATIONALE OF POSTOPERATIVE ADJUVANT THERAPY FOR LEIOMYOSARCOMA